Home/Pipeline/AGA111

AGA111

Spinal Fusion

Phase 3Active

Key Facts

Indication

Spinal Fusion

Phase

Phase 3

Status

Active

Company

Angitia Biopharmaceuticals

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a private, clinical-stage biotech with a focused pipeline of three biologic candidates targeting high-need musculoskeletal conditions, including osteoporosis and osteogenesis imperfecta. The company is led by industry veteran Dr. Hua Zhu (David) Ke, who previously contributed to the development of blockbuster bone drugs like Prolia and Evenity. With a strong financial position bolstered by a recent $130M Series D round in 2026, Angitia is advancing multiple Phase 2 trials globally while building on a foundation of proven scientific acumen in bone biology.

View full company profile

Therapeutic Areas

Musculoskeletal Diseases Osteoporosis Osteogenesis Imperfecta Spinal Disorders

Other Spinal Fusion Drugs

Drug	Company	Phase	Status
JAZBI™ Cubes	SDIP Innovations	Preclinical	Active
Expandable Interbody Portfolio	Globus Medical	Iterative Development	Active
Mimetic Metal Technology Development	CoreLink Surgical	Development/Commercial	Active
Bone Graft Substitute	BiologicsMD	Pre-clinical	Active
VisuALIF	SpineSmith	Commercial	Active
ASTRO Registry	Artoss	Post-Market	Active
Hive Smart Implant Exploration	NanoHive Medical	Pre-clinical R&D	Active
ProLift Pivot Expandable Spacer System	Life Spine	FDA Cleared	Active
NEXXT MATRIXX Clinical Evidence Study	Nexxt Spine	Post-Market Study	Active
X-PAC® Portfolio Expansion	Expanding Innovations	Development	Active
SOLACE™	Xenix Medical	Commercial	Active
TrellOss Porous Ti Interbody System	HighRidge Medical	Approved	Active